SCHEMBL20439526

SCHEMBL20439526

Cc1ccc(C(N)=O)cc1Nc1nc(-c2cccnc2)nc2c1cnn2C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.68
MAPK11 Q15759 3/20 0.68
MAPK3 P27361 3/20 0.68
ESYT2 A0FGR8 2/20 0.68
NBAS A2RRP1 2/20 0.68
CNOT1 A5YKK6 2/20 0.68
TBKBP1 A7MCY6 2/20 0.68
AGPS O00116 2/20 0.68
MYO1F O00160 2/20 0.68
SNAP23 O00161 2/20 0.68
AP3B1 O00203 2/20 0.68
PSMD12 O00232 2/20 0.68
BMPR1B O00238 2/20 0.68
PGRMC1 O00264 2/20 0.68
CLIC1 O00299 2/20 0.68
CDC7 O00311 2/20 0.68
IPO5 O00410 2/20 0.68
PLK4 O00444 2/20 0.68
COXFA4 O00483 2/20 0.68
NOP56 O00567 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24532064 0.85 ABL1 (0.74) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL24532062 0.85 ABL1 (0.82) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL29728043 0.85 PIK3CA (0.56) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL24532058 0.84 ABL1 (0.83) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL24532034 0.84 ABL1 (0.73) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL24532065 0.83 ABL1 (0.72) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL23092250 0.83 ABL1 (0.80) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL24532059 0.83 ABL1 (0.86) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL24532087 0.82 ABL1 (0.73) MAPK14MAPK11MAPK3ESYT2NBAS
SCHEMBL24532060 0.82 MAPK14 (0.77) MAPK14MAPK11MAPK3ESYT2NBAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180214449-A1 CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS UBRX, INC. 2018-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214449-A1 CANCER THERAPY USING JAK INHIBITOR IN COMBINATION WITH MAPK INHIBITORS JAK2, JAK1, JAK3 MAPK14 37/4885MAPK11 51/4885MAPK3 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.